FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion

Oncology News burst

Source: FDA Center for Drug Evaluation and Research - What's New - April 20, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news